(S)-dHTC1
(S)-dHTC1 is a stereoselective molecular glue degrader of the transcriptional coactivator ENL, binding to the ENL YEATS domain with a KD of 49 nM. After pre-forming a complex with ENL, (S)-dHTC1 cooperatively recruits CRL4CRBN through an extensive ENL-CRBN protein-protein interaction interface, promoting stereoselective ternary complex formation and inducing ENL degradation. (S)-dHTC1 can be used for research on acute myeloid leukemia (AML).
For research use only. We do not sell to patients.
- CAS No.: 3081383-46-9
- Formula: C33H40N8O6S
- Molecular Weight:676.79
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
ENL 49 nM (Kd) |
ENL 10 μM (EC50) |
In Vitro
(S)-dHTC1 (compound 7) (1 nM-100 μM; 0.5-120 h) induces dose- and time-dependent ENL degradation in MV4;11 HiBiT-ENL cells, and retains degradation activity after prolonged exposure, with only a weak high-concentration hook effect; under the same conditions, (R)-dHTC1 shows essentially no ENL degradation activity[1].
(S)-dHTC1 (1 nM-100 μM) induces varying degrees of dose-dependent ENL degradation in OCI-AML2, MOLM-13, HL-60, OCI-AML3, EOL1, and MV4;11 HiBiT-ENL cells, whereas (R)-dHTC1 is largely inactive[1].
(S)-dHTC1 binds directly to the purified ENL YEATS domain, with a KD of 49 nM determined by SPR, which is similar to the binding affinity of the inactive (R)-dHTC1 for ENL[1].
(S)-dHTC1 (1 nM-100 μM; 3 h; 1 h pre-incubation with 1 μM MLN4924) binds intracellular ENL YEATS in OCI-AML2 cells with an EC50 of 10.0 μM[1].
(S)-dHTC1 binds weakly to purified CRBNmidi as an independent binary interaction, with a KD of 63 μM as measured by SPR[1].
(S)-dHTC1 (1 nM-100 μM; 2 h; followed by dBET6 500 nM for 1 h) does not significantly antagonize dBET6-induced BRD4 degradation in MV4;11-BRD4-HiBiT cells, supporting its weak intracellular binding to CRBN as a single agent[1].
(S)-dHTC1 (1 nM-100 μM; ENL YEATS 3 μM) significantly enhances the CRBN FP competition signal in the presence of ENL YEATS, whereas it shows only a weak effect in the absence of ENL, indicating that its CRBN binding depends on the preformed ENL:(S)-dHTC1 complex[1].
(S)-dHTC1 (1 μM) promotes the binding of CRBN-DDB1 to immobilized ENL YEATS and forms a ternary complex, whereas (R)-dHTC1 with the opposite configuration hardly induces this interaction[1].
(S)-dHTC1 binds ENL with a KD of 53 nM in the absence of CRBN-DDB1 and a KD of 39 nM in the presence of CRBN-DDB1 (500 nM), indicating that ternary complex formation further stabilizes ENL binding[1].
(S)-dHTC1 (1 nM-100 μM; CRBN-DDB1 500 nM) induces ENL-CRBN-DDB1 ternary complex formation in SPR experiments and exhibits a pronounced hook effect, whereas (R)-dHTC1 shows very weak ternary complex formation capacity[1].
(S)-dHTC1 (1 nM-1 mM) induces proximity between ENL YEATS and CRBN-DDB1 in the TR-FRET assay and exhibits a hook effect, whereas (R)-dHTC1 shows very weak proximity-inducing activity[1].
(S)-dHTC1 (1 nM-100 μM; 24 h) enhances the potency and depth of ENL degradation with increasing CRBN expression in MOLM-13 HiBiT-ENL cells with different CRBN overexpression levels, whereas (R)-dHTC1 remains largely inactive[1].
(S)-dHTC1 (1 μM; 24 h) fails to effectively degrade ENL-R16A and ENL-E74A in MV4;11 ENL-TagBFP reporter cells, shows reduced degradation of ENL-K72A, while ENL-Q41A is more sensitive to it, confirming that the ENL-CRBN protein-protein interface is a key determinant of (S)-dHTC1 activity[1].
(S)-dHTC1 (39.07, 78.13, 156, 312, 625 nM, 1.25, 2.5, 5, 10 μM; 12 days; fresh compound supplemented every 3 days) inhibits ENL-dependent MV4;11 cell growth in a stereoselective and CRBN-dependent manner, with minimal effect on ENL-independent HL-60 cells; CRBN loss confers resistance to (S)-dHTC1 in MV4;11 cells, and (R)-dHTC1 has essentially no effect on either cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MV4;11 WT, MV4;11 CRBN KO, HL-60
-
Concentration:39.07, 78.13, 156, 312, 625 nM, 1.25, 2.5, 5, 10 μM
-
Incubation Time:12 days (fresh compound added every 3 days)
-
Result:Suppressed the growth/viability of ENL-dependent MV4;11 WT cells.
CRBN loss conferred resistance in MV4;11 cells.
Showed little effect on HL-60 cells.
(R)-dHTC1 showed essentially no growth-suppressive activity in either cell line.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) (female, 6-8 weeks old, orthotopic xenotransplantation model with 1 × 10^6 MV4;11 cells intravenously injected)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; every 12 h; three doses
-
Result:Stereoselectively degraded ENL in the orthotopic MV4;11 AML xenograft model after three administrations.
Stereoselectively inhibited the expression of ENL target genes as defined by ChIP-seq and dTAG-responsiveness.
Increased transcription of the myeloid differentiation marker ITGAM (encoding CD11b), confirmed by measuring cell surface expression of CD11b in the spleen and peripheral blood.
Chemical Information
-
CAS No. 3081383-46-9
-
Molecular Weight 676.79
-
Formula C33H40N8O6S
-
SMILES
O=C(NC1CCC1)C(C=C2)=CN(C2=N3)C=C3C4=CC=CC(C(NCCN5CCC(NS(=O)(N6C[C@@]7(CC(NC7=O)=O)CC6)=O)CC5)=O)=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Pull-down
The pull-down assay is an in vitro technique used to detect physical interactions between two or more proteins and an invaluable tool for confirming a predicted protein-protein interaction or identifying novel interacting partners. This method typically involves the use of affinity purification with various wash and elution steps.
-
Immunoprecipitation
Immunoprecipitation (IP) is an experimental method that uses the principle of antibody specific binding to purify and enrich target proteins.
-
Protocol for Bimolecular Fluorescence Complementation (BiFC) Assay
Bimolecular fluorescence complementation detects protein-protein proximity in living or fixed cells by fusing two candidate interaction partners to nonfluorescent N- and C-terminal fragments of a fluorescent protein; when the partners interact or remain close enough, the fluorescent fragments complement, mature, and generate a fluorescent signal at the site of the protein complex. The BiFC readout is fluorescence intensity and subcellular localization of the reconstituted fluorophore, which reflects formation or stabilization of a protein complex rather than direct biochemical binding kinetics; BiFC is therefore useful for mapping where interactions occur in cancer cells, neurons, macrophages, organoid-derived cells, or drug-screening systems, but results should be validated by independent assays such as co-IP or Western blot. BiFC signal formation is delayed by fluorophore maturation and can stabilize otherwise transient complexes, so it is not a real-time reversible interaction assay
-
Co-Immunoprecipitation
Co-immunoprecipitation technology can verify protein interaction based on the specific immune reaction between antibodies and antigens.
-
Protocol for Yeast Two-Hybrid (Y2H) Assay
The yeast two-hybrid assay detects binary protein-protein interactions by separating a transcription factor into a DNA-binding domain fused to a "bait" protein and a transcriptional activation domain fused to a "prey" protein; if bait and prey interact in yeast, the transcription factor is reconstituted and activates reporter genes such as HIS3, ADE2, lacZ, MEL1, or other selectable/readable reporters. The readout is yeast growth on selective medium and/or reporter activity, which reflects proximity-dependent transcriptional activation in the yeast nucleus rather than direct biochemical binding in the original mammalian, tumor, neuronal, macrophage, or organoid context. Because yeast two-hybrid can generate false positives and false negatives, interaction claims should be validated using independent assays such as co-immunoprecipitation, Western blot, immunofluorescence colocalization, BiFC, pull-down, or mammalian two-hybrid assays.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)